ArticleNature neuroscience2015
Exome sequencing uncovers hidden pathways in familial and sporadic ALS.
Article in Nature neuroscience, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prevalence and correlates of fatigue in amyotrophic lateral sclerosis: A systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Pooled it
- Safety and efficacy of lithium in patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis of randomized controlled trials.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023Pooled it
- Lysosomes as a therapeutic target.Nature reviews. Drug discovery · 2019Review
- Dynactin1 depletion leads to neuromuscular synapse instability and functional abnormalities.Molecular neurodegeneration · 2019Article
- Inflammation in ALS/FTD pathogenesis.Acta neuropathologica · 2019Review
- Personalized Medicine and Molecular Interaction Networks in Amyotrophic Lateral Sclerosis (ALS): Current Knowledge.Journal of personalized medicine · 2018Review
- Parkin is a disease modifier in the mutant SOD1 mouse model of ALS.EMBO molecular medicine · 2018Article
- CDC Grand Rounds: National Amyotrophic Lateral Sclerosis (ALS) Registry Impact, Challenges, and Future Directions.MMWR. Morbidity and mortality weekly report · 2017Article
- Clinical and neuropathological features of ALS/FTD with TIA1 mutations.Acta neuropathologica communications · 2017Article
- Prion Properties of SOD1 in Amyotrophic Lateral Sclerosis and Potential Therapy.Cold Spring Harbor perspectives in biology · 2017Review
- Whole exome sequencing and DNA methylation analysis in a clinical amyotrophic lateral sclerosis cohort.Molecular genetics & genomic medicine · 2017Article
- Major review: Molecular genetics of primary open-angle glaucoma.Experimental eye research · 2017Review
- Loss of C9orf72 function leads to autoimmunity.Annals of translational medicine · 2017Article
- Loss-of-function mutations in the C9ORF72 mouse ortholog cause fatal autoimmune disease.Science translational medicine · 2016Article
- Lost & found: C9ORF72 and the autophagy pathway in ALS/FTD.The EMBO journal · 2016Article
- Familial Amyotrophic Lateral Sclerosis.Neurologic clinics · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
25919956What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.